WO2025238528 - TETRAVALENT AGONISTS OF ERYTHROPOIETIN RECEPTOR
National phase entry is expected:
Publication Number
WO/2025/238528
Publication Date
20.11.2025
International Application No.
PCT/IB2025/054978
International Filing Date
13.05.2025
Title **
[English]
TETRAVALENT AGONISTS OF ERYTHROPOIETIN RECEPTOR
[French]
AGONISTES TÉTRAVALENTS DU RÉCEPTEUR DE L'ÉRYTHROPOÏÉTINE
Applicants **
EPOK THERAPEUTICS INC.
Inventors
BLAZER, Levi L.
ADAMS, Jarrett
MOE, Orson W.
SIDHU, Sachdev
Priority Data
24175368.0
13.05.2024
EP
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
CIPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2530 | |
| EPO | Filing, Examination, Granting | 17659 | |
| Japan | Filing, Examination, Granting | 2513 | |
| South Korea | Filing, Examination, Granting | 2822 | |
| USA | Filing, Examination, Granting | 6540 |
Total:
32,064
Contact Us
Abstract[English]
It forms an object of the present invention a tetravalent antibody construct capable of selectively binding with high affinity to human EPOR, acting as a hEPOR agonist. It forms a further object said antibody for use in the treatment of kidney diseases and anemias.[French]
L'objet de la présente invention est de fournir une construction d'anticorps tétravalent pouvant se lier de manière sélective à l'EPOR humain avec une affinité élevée et qui agit en tant qu'agoniste de hEPOR. Un autre objet de la présente invention est de fournir ledit anticorps destiné à être utilisé dans le traitement de maladies rénales et de l'anémie.